Recombinant Rat CD40/TNFRSF5 Fc Chimera Protein, CF

Recombinant Rat CD40/TNFRSF5 Fc Chimera (Catalog # 8229-CD) inhibitsCD40 Ligand-induced proliferation of mouse B cells. The ED50 for this effect is0.1‑0.6 μg/mL.

• Reactivity: Rt
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Rat CD40/TNFRSF5 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit CD40 Ligand-induced proliferation of mouse B cells. The ED₅₀ for this effect is 0.1-0.6 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived rat CD40/TNFRSF5 protein
  

  Rat CD40 (Val24-Arg193) Accession # Q4QQW2	IEGRMDP	Mouse IgG2A (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: Q4QQW2
• N-terminal Sequence: Val24
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: Cd40
• Purity: >95%, by SDS-PAGE with silver staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 46 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 57-63 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS and Trehalose.
• Purity: >95%, by SDS-PAGE with silver staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Rat CD40/TNFRSF5 Fc Chimera Protein, CF

• B cell surface antigen CD40
• B-cell surface antigen CD40
• Bp50B cell-associated molecule
• CD40 antigen
• CD40 molecule, TNF receptor superfamily member 5
• CD40 type II isoform
• CD40
• CD40L receptor
• CDw40
• MGC9013
• nerve growth factor receptor-related B-lymphocyte activation molecule
• p50
• TNFRSF5
• TNFRSF5CD40 antigen (TNF receptor superfamily member 5)
• tumor necrosis factor receptor superfamily member 5
• tumor necrosis factor receptor superfamily, member 5

Background

CD40, also known as TNFRSF5, is an approximately 32-35 kDa type I transmembrane glycoprotein member of the TNF receptor superfamily. The extracellular domain of rat CD40 shares 81% and 56% aa sequence identity with mouse and human CD40, respectively. Multiple rat CD40 splice variants have been reported including soluble isoforms. CD40 is expressed on the surface of B cells, dendritic cells, macrophages, monocytes and platelets, as well as endothelial and epithelial cells (1, 2). Interaction of CD40 with its ligand, CD40 Ligand, leads to the aggregation of CD40 molecules resulting in the initiation of intracellular signaling in both CD40 and CD40 Ligand expressing cells (3). CD40 ligation by CD40 Ligand promotes B cell activation and T cell-dependent humoral responses (4, 5). CD40 serves multiple functions in both hematopoietic and epithelial cancers and is a target for tumor immunotherapy (6, 7). Dysregulation of CD40/CD40 Ligand expression and interactions contributes to the immune deficiency associated with HIV infection and AIDS (8, 9). It is also implicated in the pathology of multiple cardiovascular diseases including atherosclerosis, atherothrombosis, and restenosis (10, 11).

1. van Kooten, C. and J. Banchereau (1997) Curr. Opin. Immunol. 9:330.
2. Schonbeck, U. et al. (1997) J. Biol. Chem. 272:19569.
3. Eissner, G. et al. (2004) Cytokine Growth Factor Rev. 15:353.
4. Rickert, R.C. et al. (2011) Immunol. Rev. 244:115.
5. Elgueta, R. et al. (2009) Immunol. Rev. 229:152.
6. Loskog, A.S. and A.G. Eliopoulos (2009) Semin. Immunol. 21:301.
7. Hangalapura, B.N. et al. (2012) J. Gene Med. 14:416.
8. Kornbluth, R.S. (2000) J. Leukoc. Biol. 68:373.
9. Chougnet, C. (2003) J. Leukoc. Biol. 74:702.
10. Pamukcu, B. et al. (2011) Ann. Med. 43:331.
11. Hassan, G.S. et al. (2012) Immunobiology 217:521.

Publications for CD40/TNFRSF5 (8229-CD)(1)

Publication using 8229-CD

• Kobayashi, C;Suzuki-Imaizumi, M;Sakaguchi, Y;Ishii, T;Adachi, M;Kaneda, A;Ebihara, R;Saito, M;Uemori, T;Mori, K; The novel and potent CD40 agonist KHK2840 augments the antitumor efficacy of anti-PD-1 antibody and paclitaxel Cancer science 2024-10-08 [PMID: 39380291] (Surface Plasmon Resonance (SPR), N/A)

FAQs for CD40/TNFRSF5 (8229-CD). (Showing 1 - 2 of 2 FAQ).

1. I wanna know does CD40 antibody for IHC-P comes with positive control slide?
   • Our CD40 antibodies do not come with positive control slides however you can use any type of primary carcinoma cell as a positive control. I recommend breast carcinoma as this is what we have tested our CD40 antibodies on.
2. We are studying CD40L in our system. It has been known that both CD40 and CD11b are receptors for CD40L. We need CD40 antibody to neutralize CD40 binding to CD40L, then we may prove what is function for CD11b binding to CD40L. Do you have any CD40 Ab which has block function only between CD40 and CD40L, but not between CD11b and CD40L?
   • Unfortunately, none of our CD40 antibodies have been specifically tested for this application.

Bioinformatics

• Gene Symbol: Cd40
• Uniprot:
  • Q4QQW2()